Evidence map›Paper›PMID 41930342›Full record

ReviewMedComm2026

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery.

Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengqing ZhaoState Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Industrial Biotechnology School of Life Sciences Hubei University Wuhan China.
Wenhao YinState Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Industrial Biotechnology School of Life Sciences Hubei University Wuhan China.
Jianjian HanState Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Industrial Biotechnology School of Life Sciences Hubei University Wuhan China.
Huimin WangState Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Industrial Biotechnology School of Life Sciences Hubei University Wuhan China.
Zheng LiuDepartment of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Lilong LiuDepartment of Urology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.ORCID https://orcid.org/0000-0001-5459-5204
Wuxiang MaoState Key Laboratory of Biocatalysis and Enzyme Engineering Hubei Province Key Laboratory of Industrial Biotechnology School of Life Sciences Hubei University Wuhan China.ORCID https://orcid.org/0000-0001-7213-3062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular and membrane proteins serve important roles. They manage cellular communication, structure support, and immune defense. When they malfunction, it cause many diseases like cancer, neurodegeneration, and cardiovascular disorders. Targeted protein degradation (TPD) is a promising therapeutic strategy and aims to remove these faulty proteins. This approach goes beyond traditional drugs, which only block the active site of proteins. The aim of TPD is to entirely remove the targeted proteins in cells. This review began with explaining the structure and functions of extracellular and membrane proteins, highlighting their connection with disease. It then went on to discuss new strategies for their degradation. These emerging strategies include those that take advantage of cell-surface receptors to target lysosomes, intracellular lysosomal sorting tools, E3 ligases, and nanoparticle-based systems. A comparison of different TPD tools was also provided. Discussion compared strengths and weaknesses of approaches with small molecules, antibodies, nanobodies, and aptamers. Finally, the review outlined future directions for advanced TPD strategies. Next steps would be the combination of degraders with therapeutic antibodies. Another research interest is the utilization of tissue-specific receptors from genetic databases. Moreover, the application of TPD to immune and neurodegenerative diseases is also a critical goal for the future.

Indexed as

drug discoveryextracellular proteinsLYTACmembrane proteinsPROTACTPD

Identifiers

PMID41930342
PMCPMC13042399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.